JP2024529839A5 - - Google Patents
Info
- Publication number
- JP2024529839A5 JP2024529839A5 JP2023580379A JP2023580379A JP2024529839A5 JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5 JP 2023580379 A JP2023580379 A JP 2023580379A JP 2023580379 A JP2023580379 A JP 2023580379A JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5
- Authority
- JP
- Japan
- Prior art keywords
- caution
- membered
- alkyl
- heterocycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216446P | 2021-06-29 | 2021-06-29 | |
| US63/216,446 | 2021-06-29 | ||
| US202263320155P | 2022-03-15 | 2022-03-15 | |
| US63/320,155 | 2022-03-15 | ||
| PCT/US2022/035306 WO2023278438A1 (en) | 2021-06-29 | 2022-06-28 | Nlrp3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529839A JP2024529839A (ja) | 2024-08-14 |
| JP2024529839A5 true JP2024529839A5 (cg-RX-API-DMAC7.html) | 2025-06-30 |
Family
ID=84692056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580379A Pending JP2024529839A (ja) | 2021-06-29 | 2022-06-28 | Nlrp3モジュレーター |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240327413A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4362946A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529839A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202319054A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023278438A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| TW202231281A (zh) * | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| PL4363406T3 (pl) | 2021-07-02 | 2026-01-05 | Astrazeneca Ab | Inhibitory inflamasomu nlrp3 |
| CA3226995A1 (en) * | 2021-07-21 | 2023-01-26 | Nico Therapeutics, Inc. | Annulated pyridazine compound |
| IL310992A (en) * | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技(浙江)有限公司 | 一种含氮化合物、其制备方法及应用 |
| CN118234730A (zh) * | 2021-11-17 | 2024-06-21 | 豪夫迈·罗氏有限公司 | 杂环nlrp3抑制剂 |
| EP4499646A4 (en) * | 2022-03-31 | 2026-03-18 | Hangzhou Highlightll Pharmaceutical Co Ltd | NLRP3 Inflammasome Inhibitors |
| WO2024006559A1 (en) * | 2022-07-01 | 2024-01-04 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| CN120569372A (zh) * | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| EP4658649A1 (en) * | 2023-01-31 | 2025-12-10 | Janssen Pharmaceutica NV | [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors |
| JP2026504422A (ja) | 2023-01-31 | 2026-02-05 | ヤンセン ファーマシューティカ エヌ.ベー. | NLRP3阻害剤としてのピロロ[1,2-d][1,2,4]トリアジン及びピラゾロ[1,5-d][1,2,4]トリアジン |
| WO2024160692A1 (en) * | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors |
| TW202448892A (zh) * | 2023-04-17 | 2024-12-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠合噠嗪類衍生物及其用途 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026082103A1 (zh) * | 2024-10-16 | 2026-04-23 | 青岛博森泰科技有限公司 | 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途 |
| WO2026082092A1 (zh) * | 2024-10-16 | 2026-04-23 | 青岛博森泰科技有限公司 | 一种nlrp3抑制剂用于治疗炎症的用途 |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919957D0 (en) * | 1999-08-23 | 1999-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| EP1745039A4 (en) * | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021009567A1 (en) * | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
-
2022
- 2022-06-28 JP JP2023580379A patent/JP2024529839A/ja active Pending
- 2022-06-28 US US18/574,530 patent/US20240327413A1/en active Pending
- 2022-06-28 WO PCT/US2022/035306 patent/WO2023278438A1/en not_active Ceased
- 2022-06-28 EP EP22834059.2A patent/EP4362946A4/en active Pending
- 2022-06-29 TW TW111124256A patent/TW202319054A/zh unknown